Recent data suggests that retatrutide, a dual-action medication, might represent a major improvement in body management. This therapy combines the effects of a GLP-1 agonist and a GIP agonist , possibly offering a more benefit than existing approaches . Study trials have demonstrated encouraging findings , including considerable decreases in size a